Osteoporosis and Sarcopenia最新文献_第7页

Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats 特立帕肽和依替卡西肽可改善慢性肾病模型大鼠的骨骼、纤维化和脂肪参数。

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.002

Shun Igarashi , Yuji Kasukawa , Koji Nozaka , Hiroyuki Tsuchie , Kazunobu Abe , Hikaru Saito , Ryo Shoji , Fumihito Kasama , Shuntaro Harata , Kento Okamoto , Keita Oya , Naohisa Miyakoshi

{"title":"Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats","authors":"Shun Igarashi , Yuji Kasukawa , Koji Nozaka , Hiroyuki Tsuchie , Kazunobu Abe , Hikaru Saito , Ryo Shoji , Fumihito Kasama , Shuntaro Harata , Kento Okamoto , Keita Oya , Naohisa Miyakoshi","doi":"10.1016/j.afos.2023.11.002","DOIUrl":"10.1016/j.afos.2023.11.002","url":null,"abstract":"<div><h3>Objectives</h3><div>Chronic kidney disease (CKD) complicated by secondary hyperparathyroidism (SHPT) is associated with an increased risk of fragility fractures. Etelcalcetide (EC) is a treatment for SHPT that reduces serum parathyroid hormone (PTH) levels. However, the effects of combined treatment with osteoporosis drugs such as teriparatide (TPTD) remain unclear. This study investigates the combined effects of EC and TPTD on bone in CKD model rats.</div></div><div><h3>Methods</h3><div>The CKD model was established in 8-week-old male Wistar rats by feeding them a 0.75% adenine diet for 4 weeks. At 20 weeks of age, the rats were divided into 4 groups (N = 9–10 in each group): CKD group (vehicle administration), TPTD group (30 μg/kg, 3 times/week), EC group (0.6 mg/kg, daily), and Comb group (TPTD and EC combined). EC was injected for 12 weeks starting at 20 weeks of age, and TPTD was injected for 8 weeks starting at 24 weeks of age. After treatment, the followings were evaluated: bone mineral density, bone strength, biochemical tests, bone and fat histomorphometry, and micro-computed tomography.</div></div><div><h3>Results</h3><div>In CKD model rats, the combination of EC and TPTD was more effective in increasing cortical bone thickness and bone strength and inhibiting porosity. In addition, the combined treatment decreased bone marrow adiposity and fibrosis, and it increased bone mass and improved bone microstructure in trabecular bone.</div></div><div><h3>Conclusions</h3><div>With the observed benefits such as improved bone mass, bone strength, structural properties, and bone marrow adiposity, combination therapy may be a potential way to improve bone fragility in CKD.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"9 4","pages":"Pages 121-130"},"PeriodicalIF":2.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139907270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Resistance training and nutritional support improve sarcopenia with favorable changes in metabolomics and lipidomics

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.030

Wei-Hsiang Hsu , San-Yuan Wang , Yen-Ming Chao , Ke-Vin Chang , Der-Sheng Han , Yun-Lian Lin

引用次数: 0

The effects of integrated osteoporosis education on osteoporosis knowledge, attitude, behavior and quality of life among middle-aged and elderly osteoporosis patients

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.028

I-Chin Huang , Chih-Lung Lin , Hsiu-Hung Wang

引用次数: 0

Comparison of refracture and mortality of forearm fracture in middle-aged and elderly people with or without combination of traditional Chinese and western medicine

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.041

Ching-Feng Cho , Chia-Chun Li , Ta-Wei Tai , Ching-Ju Chiu , Chih-Hsing Wu

引用次数: 0

Associations between a high ‘calcium, potassium and protein’ dietary pattern, osteopenia and osteoporosis in older adults in Malaysia

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.017

Vaidehi Ulaganathan , Geeta Appannah , Subashini C. Thambiah , Swan Sim Yeap , Intan Nureslyna Samsudin , Salmiah Md-Said , Siti Yazmin Zahari-Sham , Fen Lee Hew , Subapriya Suppiah

引用次数: 0

A hand surgery nurse specialist clinic improves rate of osteoporosis screening and education

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.019

SzeHuey Chan , F. Johari

引用次数: 0

Effects of Teriparatide versus Vertebroplasty on pain control and radiographic outcomes after osteoporotic vertebral compression fracture

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.033

Chi-Chien Niu , Po-An Chen , Ping-Yeh Chiu , Fu-Cheng Kao , Ming-Kai Hsieh , Tsung-Ting Tsai , Po-Liang Lai , Tsai-Sheng Fu

引用次数: 0

Treatment persistence and medication switch associated with subsequent fractures after osteoporotic fractures

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.005

Sung-Yen Lin , Yi-Ming Chen , Li-Nien Chien , Chung-Hwan Chen

引用次数: 0

Osteoporosis case manager intervention to improve medication possession ratio among osteoporotic patients with anti-osteoporotic medication for fragility fracture

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.11.024

Chia-Tien Hsu , Ya-Lien Teng , Shih-Yi Lin , Hsu-Tung Lee

引用次数: 0

Pain score as a predictor of subsequent fragility fracture in postmenopausal patients with rheumatoid arthritis: A retrospective case-control study 疼痛评分是绝经后类风湿性关节炎患者发生脆性骨折的预测因素：一项回顾性病例对照研究

IF 2.5

Osteoporosis and Sarcopenia Pub Date : 2023-12-01 DOI: 10.1016/j.afos.2023.12.001

Ichiro Yoshii , Naoya Sawada , Tatsumi Chijiwa

{"title":"Pain score as a predictor of subsequent fragility fracture in postmenopausal patients with rheumatoid arthritis: A retrospective case-control study","authors":"Ichiro Yoshii , Naoya Sawada , Tatsumi Chijiwa","doi":"10.1016/j.afos.2023.12.001","DOIUrl":"10.1016/j.afos.2023.12.001","url":null,"abstract":"<div><h3>Objectives</h3><div>Bone fragility fracture (BFF) is a serious incident in treating rheumatoid arthritis (RA). We hypothesized that pain degree during treatment RA correlated with incident BFF and validated how pain affects incident BFF (inc-BFF).</div></div><div><h3>Methods</h3><div>Postmenopausal RA patients treated for at least 3 years were recruited. The primary endpoint was the development of inc-BFF. Follow-up began with the first bone mineral density measurement (baseline) and continued until the development of the first BFF or termination of the study. Clinical indicators at baseline, including pain score using a visual analog scale (PS-VAS), were analyzed statistically using Cox regression analysis, receiver operation characteristics (ROC), Kaplan-Meier survival curve analysis (K-M), and chi-square test.</div></div><div><h3>Results</h3><div>A total of 239 patients were recruited. Using a multivariate Cox regression analysis, the baseline's PS-VAS and prevalent BFF (pr-BFF) demonstrated significantly higher risk ratios. For ROC, pr-BFF and PS-VAS had significant cutoff index (COI) (positive, 21.0) and an area under-curve of 0.692 (P < 0.001) and 0.616 (P < 0.01), respectively. PS-VAS > COI had a 2.24-fold higher hazard ratio than PS-VAS ≤ COI using K-M. When these 2 conditions were combined, patients with pr-BFF-positive and PS-VAS-positive had a sensitivity of 42.3% and a specificity of 88.8% for the inc-BFF. PS-VAS > COI had no statistical significance in the subgroup without pr-BFF, whereas the existence of pr-BFF had a significantly higher risk ratio in the PS-VAS ≤ COI.</div></div><div><h3>Conclusions</h3><div>The PS-VAS during RA treatment is a good indicator for predicting the inc-BFF in postmenopausal RA patients with pr-BFF.</div></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"9 4","pages":"Pages 150-156"},"PeriodicalIF":2.5,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139014638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0